Last week I blogged about a study that showed how some dementia drugs may help reduce the progression of the disease and delay admission to care homes for people with the condition. This new systematic review carried out by a research team from Harvard Medical School investigates the potential side effects of two dementia drugs: [read the full story…]
The evidence-base for psychodynamic psychotherapy is growing. A meta-analysis by Shedler published in early 2010 showed that the effect sizes for psychodynamic therapy can be as large as for other ’empirically supported treatments’. However, there are fewer high quality studies available that look at the effectiveness of these therapies for young people. This systematic review [read the full story…]
Researchers from Nottingham University have published a meta-review that aims to evaluate the quality of existing reviews and to enable reliable comparisons of alternative computerised cognitive behaviour therapy (cCBT) packages for treating mild to moderate depression with or without anxiety. The reviewers conducted a systematic search and found 12 systematic reviews from 10 studies covering [read the full story…]
Researchers from Oxford University’s Centre for Suicide Research have conducted a systematic review of qualitative and quantitative studies that explore health service staff attitudes to people who self-harm. It’s obvious to say that staff attitudes are going to have a big impact on the care of patients, but this research sought to review the nature [read the full story…]
Attention deficit hyperactivity disorder (ADHD) is a group of behavioural symptoms that include inattentiveness, hyperactivity and impulsiveness. ADHD is often thought of as a childhood problem, but it can be a lifelong condition, and many children continue to have symptoms as a teenager and adult. It is estimated that nearly two-thirds of children with ADHD [read the full story…]
First generation typical antipsychotics (e.g. chlorpromazine and haloperidol) have historically been used a great deal to treat people with schizophrenia. More recently, second-generation atypical antipsychotics (e.g. risperidone and olanzapine) have been more frequently used. For many, these drug therapies help to reduce psychotic episodes and the overall impact of the illness, but not all patients [read the full story…]
Every once in a while the Cochrane library publish an overview of reviews to summarise the evidence for a specific intervention. Such an overview has recently been made available to bring together all of the Cochrane reviews that assess the effectiveness and safety of pharmacological interventions in the treatment of alcohol withdrawal. The overview brings [read the full story…]
The researchers in this review looked at findings related to melatonin in autism spectrum disorders (ASD), including autistic disorder, Asperger syndrome, Rett syndrome, and pervasive developmental disorders, not otherwise specified. From a search of databases, they were able to find 35 studies that met review’s inclusion criteria. It was possible to perform a meta-analysis on [read the full story…]
A group of researchers from Dresden in Germany have recently updated a review they originally published in 2005, which provides 12-month prevalence and disability burden estimates of a broad range of mental and neurological disorders in the European Union (EU). Their review included studies from all 27 EU member states plus Switzerland, Iceland and Norway [read the full story…]
People with severe mental illnesses like schizophrenia or bipolar disorder are over three times more likely to lose their teeth because of poor oral health than the general population. The research, published in the September issue of the British Journal of Psychiatry, shows that psychiatric patients have not shared in recent improvements in dental health. [read the full story…]
